Warning Letter — GC America, Inc.
The FDA issued a Warning Letter to GC America, Inc. following an inspection by the Center for Drug Evaluation and Research (CDER).
This update affects GC America, Inc., as well as regulatory and quality assurance professionals responsible for oversight of drug manufacturing facilities regulated by CDER.
A Warning Letter from CDER typically indicates significant deviations from Current Good Manufacturing Practice (CGMP) or other regulatory requirements. Failure to address the issues cited may lead to further enforcement actions, such as seizure, injunction, or the withholding of product approvals. The source provides limited detail on the specific violations, but the issuance by CDER suggests concerns related to drug quality or manufacturing integrity.
Quality and regulatory teams should perform a comprehensive audit of current manufacturing and quality control procedures to ensure alignment with CGMP standards. Companies receiving such letters should prepare a formal, detailed remediation plan addressing the specific deficiencies cited by CDER.
FDA Warning Letter issued to: GC America, Inc.. 05/14/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gc-america-inc-727602-05142026
Open in openFDA / FDA.gov